No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALLK Allakos
- 1.120
- -0.050-4.27%
Close Jun 18 16:00 ET
99.17MMarket Cap-455P/E (TTM)
1.170High1.100Low234.02KVolume1.170Open1.170Pre Close263.94KTurnover0.40%Turnover RatioLossP/E (Static)88.54MShares5.64052wk High0.95P/B66.27MFloat Cap0.98052wk Low--Dividend TTM59.17MShs Float157.980Historical High--Div YieldTTM5.98%Amplitude0.980Historical Low1.127Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Offer Insights on Healthcare Companies: Clene (CLNN) and Allakos (ALLK)
Express News | Allakos Says First Patient Has Been Dosed In Phase 1 Trial Of AK006 In Chronic Spontaneous Urticaria
Express News | Allakos Inc - Top-Line Phase 1 Csu Results Expected at Year End 2024
Express News | Allakos Announces First Patient Dosed in Phase 1 Trial of Ak006 in Chronic Spontaneous Urticaria
Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions
Comments
$Allakos(ALLK.US$ Allakos Announces First Patient Dosed in Phase 1 Trial of Ak006 in Chronic Spontaneous Urticaria! Top-Line Phase 1 Csu Results Expected at Year End 2024
1
$Allakos(ALLK.US$ mark my words buyout rumors or news in 2-3 months
$Allakos(ALLK.US$ Allakos | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.8%)
SEC announcement
·
01/29 17:30
SEC announcement
·
01/29 17:30
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg